Lutetium 177 PNT 6555 - POINT Biopharma
Alternative Names: 177Lu PNT6555; Lutetium-177-PNT-6555; PNT2004-177Lu-PNT6555Latest Information Update: 01 Jan 2024
At a glance
- Originator Tufts University School of Medicine
- Developer POINT Biopharma
- Class Antineoplastics; Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours